Perigon Wealth Management LLC Purchases 5,524 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Perigon Wealth Management LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,729 shares of the medical research company's stock after acquiring an additional 5,524 shares during the period. Perigon Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $18,434,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Moneta Group Investment Advisors LLC grew its position in Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company's stock worth $4,601,150,000 after acquiring an additional 8,347,260 shares during the last quarter. Providence Capital Advisors LLC grew its position in Thermo Fisher Scientific by 61,754.7% during the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company's stock worth $10,136,000 after acquiring an additional 5,832,730 shares during the last quarter. Norges Bank bought a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $3,105,677,000. Morgan Stanley grew its position in Thermo Fisher Scientific by 17.7% during the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company's stock worth $6,459,629,000 after acquiring an additional 1,764,312 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in Thermo Fisher Scientific by 61,995.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company's stock worth $535,923,000 after acquiring an additional 1,008,045 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.1 %

Thermo Fisher Scientific stock traded up $0.60 during mid-day trading on Thursday, hitting $574.31. The company had a trading volume of 1,295,086 shares, compared to its average volume of 1,558,743. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The stock's 50 day moving average price is $570.95 and its two-hundred day moving average price is $525.02. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a market capitalization of $218.99 billion, a PE ratio of 37.04, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company's quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.40 earnings per share. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio is currently 10.10%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Barclays lowered Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and lifted their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Robert W. Baird reiterated an "outperform" rating and issued a $670.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. HSBC began coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a "buy" rating and a $610.00 price objective on the stock. Wolfe Research started coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an "outperform" rating and a $575.00 price target on the stock. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $601.56.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.